Business Wire

CA-ALKIRA

27.4.2022 13:02:08 CEST | Business Wire | Press release

Share
Alkira Launches Free Tool to Tame Cloud Bloat

Cloud networking pioneer Alkira today launched Cloud Insights, a free tool to improve the networking and security of enterprise cloud deployments. Nearly a third (32%) of cloud spending is wasted, according to Flexera’s State of the Cloud Report 2022, which identifies optimization of existing cloud resources as the top priority for enterprises.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005119/en/

Cloud spending and network complexity accelerated during the pandemic, putting further pressure on businesses to optimize their cloud deployments. Growth shows no sign of slowing this year, as IDC forecasts a 21.7% increase in cloud infrastructure spending for the rest of 2022.

Alkira Cloud Insights helps cloud architects and networking admins regain control of their cloud infrastructure. The tool provides tailored recommendations on how to improve security, optimize spend and boost cloud networking performance in Amazon AWS and Microsoft Azure environments. It can help uncover duplicate IP addresses, unsanctioned internet access, unused networks and security resources, misconfigured security group settings, and unaccounted for shadow IT resources, among other things.

“Many organizations dramatically increased their cloud deployments at the beginning of Covid to support remote work and digital transformation,” said Amir Khan, CEO and founder of Alkira. “Because the shift was so sudden, many organizations' initial focus was on just making things work; the deployments were far from optimized. Alkira Cloud Insights allows businesses to do what equates to a bit of ‘spring cleaning’ for their environments. The tool helps to streamline cloud deployments, improve security posture and eliminate costly waste.”

Cloud Insights performs a rapid discovery of an organization’s AWS and Azure cloud networking environments. Companies will get a complete and automated inventory of their networking and security resources. They’ll also receive actionable data, including recommendations to improve cloud usage, security and spend. The insights and findings are delivered in an easy to use, centralized dashboard. There is also the ability to configure automated reporting to keep up to date on dynamic changes made to the cloud network environment.

Brad Casemore, Research Vice President, Datacenter and Multicloud Networks, IDC, said: “Networks that enable and support hybrid and multicloud should be sufficiently intelligent to perform optimally across an increasingly distributed landscape of cloud workloads and end points. But it all starts with meaningful audit and discovery, determining and understanding what workloads are running in which clouds, and providing insight into the networks and security postures associated with those workloads.

“Only with that foreknowledge can enterprises gain actionable insights that yield valuable business benefits and outcomes. With Cloud Insights, Alkira offers customers a free tool that helps to provide a foundational understanding of their cloud environments, setting the stage for informed enhancements that improve the agility, efficiency, performance, resiliency, and security of cloud networking.”

Existing customers get immediate access to Cloud Insights through the Alkira portal. The company is also making it freely available at https://www.alkira.com/cloud-insights to other enterprise teams looking for a quicker and easier way to audit their cloud estate.

About Alkira

Alkira is the leader in cloud networking as a service . We unify multiple clouds, sites, and users via an enterprise network built entirely in the cloud. Our Cloud Exchange Points auto-create this network plumbing and when deployed to multiple locations auto-connect to form a global fabric – all done with point and click integration of best-of-breed security and networking services. The network is managed using the same controls, policies, and security network admins know, can instantly scale as needed, and is available as a service. There is no new hardware to deploy, no software to download and no cloud architecture to learn. Alkira’s solution is trusted by Fortune 100 enterprises, leading system integrators and global managed service providers. Learn more at alkira.com and follow us @alkiranet .

Video Tour: https://youtu.be/jBQipdute44

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye